

Mental Health Medication Advisory Committee Meeting
Meeting Minutes, Open Session
February 13, 2018 at 2 pm – 4:30 pm

MHMAC
 Open Session
 DXC Technology
 Capital Room
 6511 SE Forbes Ave,
 Topeka, KS 66619

Committee Members Present:

DeAnn Jenkins, MD (Chair)
 Holly Cobb, ARNP
 Bradley Grinage, MD
 Rebecca Klingler, MD
 Charles Millhuff, DO
 Taylor Porter, MD

Committee Members Absent:

Vishal Adma, MD, MS, CMQ, CPE
 Nicole Ellermeier, PharmD
 Karen Moeller, PharmD, BCPP

KDHE Staff Present:

Ashley Goss, Deputy Secretary for Public Health, KDHE
 Dr. Greg Lakin, DO, Medicaid Medical Director, State Chief Health Officer, KDHE and DHCF
 Annette Grant, RPh, KDHE/DHCF
 Roxanne Chadwell, PharmD, CSP, KDHE/DHCF
 Carol Arace, KDHE/DHCF

MCO Representatives Present:

Jennifer Murff, RPh – United Healthcare
 Lisa Todd, RPh, BBA – Amerigroup
 Angie Zhou, Pharm. D. – Sunflower

DXC/HID Staff Present:

Karen Kluczykowski, RPh (phone)
 Kathy Kasewum
 Ellen McCaffrey

Representatives:

William Mack,
 Amerigroup; Bonnie
 Crum, Medical Student;
 Brigitte Shumann,
 FSGC

*Illegible names on the
 sign in sheet were not
 included.

	DISCUSSION	DECISION AND/OR ACTION
I. Call to Order A. Introductions B. Announcements	Call to Order: Dr. Jenkins called the meeting to order at 2:00pm. All individuals at the table introduced themselves. Announcements: Ms. Grant welcomed Dr. Jenkins as the new chair for the MHMAC and introduced Dr. Chadwell as the new Kansas Pharmacy Assistant Program Manager.	
II. Old Business A. Review and Approval of May 9, 2017 Meeting Minutes	Committee Discussion: Ms. Grant noted to the Committee that the minutes would now be in synopsis instead of word-for-word and that all previous, present, and future minutes would be posted to the Kansas Department of Health and Environment Pharmacy website once approved. Dr. Klingler; Motion to approve. Dr. Porter; Second the motion.	The minutes for the May 9, 2017 MHMAC meeting approved unanimously.
II. Old Business B. Review and Approval of August 8, 2017 Meeting Minutes	Committee Discussion: Page 57: second to last paragraph should have been referenced to Dr. Millhuff. The minutes will be amended to show this correction. Dr. Porter: Motion to approve as amended. Dr. Millhuff: Second the motion.	The minutes for the August 8, 2017 MHMAC meeting were approved as amended unanimously.
II. Old Business C. Prior Authorization Criteria 1. Adult Benzodiazepine Dosing Limits	Clinical Public Comment: - No requests were received. Background: Discussed during the August 8, 2017 meeting and brought back for finalizing. Committee Discussion: Ms. Grant requested a specific age be noted instead of just ‘adult’. Onfi® is not included in this PA criteria due to its current exclusive use as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years and older. Length of approval for most states is either 6 or 12 months. Our length of approval is 12 months. Patients on Benzos and Opioids, would follow CDC recommendations. The Committee agreed to change the title to “ORAL Benzodiazepine Dosing Limits for ≥18 Years of Age”. The committee revised and approved dose limits, as well as addition of K-TRACS monitoring and concurrent CNS depressant drug use safety criteria.	Dr. Porter motion to approve as amended. Ms. Cobb seconded the motion. The motion carried unanimously.
III. New Business A. Prior Authorization	Clinical Public Comment: - No requests were received. Background: Ms. Grant proposed a title change to age ≥18 yrs.; adding a written peer-to-peer option; addition of	Dr. Grinage motion to approve as amended.

	DISCUSSION	DECISION AND/OR ACTION
Criteria 1. Adult Antipsychotic Dosing Limits–New Drug Strengths Available, Age Change	Versacloz®, Loxitane®, Molindone®, and Compro®; two strengths added (Aristada®-1064mg and Olanzapine pamoate-405mg). Committee Discussion: Dr. Grinage motion to approve. Dr. Porter seconded the motion. The motion carried unanimously.	Dr. Porter seconded the motion. The motion carried unanimously.
III. New Business B. Prior Authorization Criteria 1. Antipsychotic Use in the Long Term Care (LTC) Population for ages ≥65 Years of Age	Clinical Public Comment: - No requests were received. Background: Based on CMS findings with Kansas having LTC patients on antipsychotic medications without having a proper diagnosis. Committee Discussion: General discussion was had, but will bring back to next meeting. Ms. Grant will send the CMS document, as well as some APA documents to the members of the Committee for further review. Committee members were urged to send their concerns and recommendations via email to Ms. Grant. The goal is to have only patients with proper diagnosis receiving the medications.	Discussion only.
IV. Open Public Comment*	Clinical Public Comment: - No requests were received. Committee Discussion: Dr. Millhuff requested Ms. Grant to address Quillivant XR, as it is not currently available for ADHD and it has been the first line treatment option. The administrative burden of the PA process was discussed. Ms. Grant noted taking the information back internally for discussion.	
V. Adjourn	Committee Discussion: Dr. Porter: Motion to adjourn. Dr. Klingler: Second the motion.	Dr. Jenkins adjourned the February 13, 2018 MHMAC meeting at 4:17pm.
<p>*Clinical and open public comment requests and written testimony must be submitted one week prior to meeting to Annette.Grant@ks.gov. If providing clinical comment, please indicate which agenda item you are requesting time to comment. Time limits during period of comment will be determined based on number of requests received. The next MHMAC meeting is scheduled for May 8, 2018.</p>		